| Detected | Trial | Change |
|---|---|---|
| 2026-06-03 | NCT03786783 Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly… |
Trial completed |
| 2026-06-03 | NCT03786783 Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly… |
date change Completion moved earlier: 2026-09-19 -> 2026-03-31 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT03126916 | Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With… | Ganglioneuroblastoma | Recruiting |
| Phase 2/3 | |||
| NCT02339571 | A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced… | Stage III Cutaneous Melanoma AJCC v7 | Active, Not Recruiting |
| Phase 2 | |||
| NCT06528496 | N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in… | High-risk Neuroblastoma | Recruiting |
| NCT07078604 | A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1… | Anatomic Stage IV Breast Cancer AJCC v8 | Recruiting |
| NCT04237623 | GM-CSF With Post-Transplant Cyclophosphamide | Transplant-Related Hematologic Malignancy | Recruiting |
| NCT04902703 | Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's… | Alzheimer Disease | Recruiting |
| NCT04936529 | A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma | Neuroblastoma | Recruiting |
| NCT06202066 | Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients… | Digestive System Neuroendocrine Neoplasm | Recruiting |
| NCT07085338 | A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy… | Neuroblastoma Recurrent | Recruiting |
| NCT06450041 | NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb)… | Neuroblastoma | Recruiting |
| NCT07327411 | Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced… | Advanced Refractory Solid Tumors | Not Yet Recruiting |
| NCT03794349 | Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in… | High Risk Neuroblastoma | Active, Not Recruiting |
| NCT02455557 | SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed… | Glioblastoma | Active, Not Recruiting |
| NCT05242965 | A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV… | Lung Non-Small Cell Carcinoma | Active, Not Recruiting |
| NCT05455658 | STEMVAC in Patients With Early Stage Triple Negative Breast Cancer | Anatomic Stage IB Breast Cancer AJCC v8 | Active, Not Recruiting |
| NCT01134614 | Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV… | Advanced Melanoma | Active, Not Recruiting |
| NCT03600350 | pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer | Prostate Cancer | Active, Not Recruiting |
| NCT07169617 | Testing the SurVaxM Vaccine for Lung Cancer Prevention | Lung Carcinoma | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for… | Anatomic Stage III Breast Cancer AJCC v8 | Recruiting |
| NCT07437963 | Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come… | Recurrent Ganglioneuroblastoma | Not Yet Recruiting |
| Phase 1 | |||
| NCT04144023 | A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma… | Breast Ductal Carcinoma In Situ | Recruiting |
| NCT05544968 | Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic… | Hodgkin Disease | Recruiting |
| NCT07374029 | Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML | Acute Myeloid Leukemia | Recruiting |
| NCT06799026 | A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in… | Multiple Myeloma | Recruiting |
| NCT07377435 | DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM | Multiple Myeloma | Recruiting |